DE69624801D1 - Stabile arzneistoffabgabekomplexe mit lipiden und verfahren zu deren herstellung - Google Patents

Stabile arzneistoffabgabekomplexe mit lipiden und verfahren zu deren herstellung

Info

Publication number
DE69624801D1
DE69624801D1 DE69624801T DE69624801T DE69624801D1 DE 69624801 D1 DE69624801 D1 DE 69624801D1 DE 69624801 T DE69624801 T DE 69624801T DE 69624801 T DE69624801 T DE 69624801T DE 69624801 D1 DE69624801 D1 DE 69624801D1
Authority
DE
Germany
Prior art keywords
drug delivery
production
complexes
lipids
stable drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69624801T
Other languages
English (en)
Other versions
DE69624801T2 (de
Inventor
Xiang Gao
Leaf Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of DE69624801D1 publication Critical patent/DE69624801D1/de
Application granted granted Critical
Publication of DE69624801T2 publication Critical patent/DE69624801T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69624801T 1995-01-23 1996-01-23 Stabile arzneistoffabgabekomplexe mit lipiden und verfahren zu deren herstellung Expired - Lifetime DE69624801T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/376,701 US5795587A (en) 1995-01-23 1995-01-23 Stable lipid-comprising drug delivery complexes and methods for their production
PCT/US1996/000816 WO1996022765A1 (en) 1995-01-23 1996-01-23 Stable lipid-comprising drug delivery complexes and methods for their production

Publications (2)

Publication Number Publication Date
DE69624801D1 true DE69624801D1 (de) 2002-12-19
DE69624801T2 DE69624801T2 (de) 2003-04-10

Family

ID=23486103

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69624801T Expired - Lifetime DE69624801T2 (de) 1995-01-23 1996-01-23 Stabile arzneistoffabgabekomplexe mit lipiden und verfahren zu deren herstellung

Country Status (14)

Country Link
US (5) US5795587A (de)
EP (1) EP0814777B1 (de)
JP (1) JP4074338B2 (de)
CN (1) CN1177291A (de)
AT (1) ATE227563T1 (de)
AU (1) AU709773B2 (de)
CA (1) CA2211118C (de)
DE (1) DE69624801T2 (de)
DK (1) DK0814777T3 (de)
ES (1) ES2186769T3 (de)
IL (1) IL116856A0 (de)
PT (1) PT814777E (de)
WO (1) WO1996022765A1 (de)
ZA (1) ZA96503B (de)

Families Citing this family (344)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
FR2727679B1 (fr) * 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US6258792B1 (en) 1996-04-12 2001-07-10 University Of Pittsburgh Cationic cholesteryl derivatives containing cyclic polar groups
CA2251543A1 (en) * 1996-04-12 1997-10-23 University Of Pittsburgh Novel cationic cholesteryl derivatives containing cyclic polar groups
AU727447B2 (en) * 1996-07-03 2000-12-14 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
CA2264012C (en) 1996-08-13 2011-04-26 Chiron Corporation Compositions and methods for polynucleotide delivery
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
JP2001510457A (ja) * 1996-11-12 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ送達に有効な、脂質―核酸複合体の安定な製剤の調製
US5962429A (en) * 1996-11-22 1999-10-05 University Of Iowa Complexes of adenovirus with cationic molecules
US7083786B2 (en) * 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US5948878A (en) * 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery
US6436708B1 (en) 1997-04-17 2002-08-20 Paola Leone Delivery system for gene therapy to the brain
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
US7157098B1 (en) * 1998-01-06 2007-01-02 Roman Perez-Soler Gene therapy of tumors using non-viral delivery system
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7244714B1 (en) * 1998-06-12 2007-07-17 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
JP4854853B2 (ja) 1998-11-12 2012-01-18 ライフ テクノロジーズ コーポレーション トランスフェクション薬剤
US6855549B1 (en) 1998-11-23 2005-02-15 The University Of Iowa Research Foundation Methods and compositions for increasing the infectivity of gene transfer vectors
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6395511B1 (en) * 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
AU2460900A (en) * 1999-02-15 2000-08-29 Nippon Shinyaku Co. Ltd. Shortened-chain polynucleotides and process for the preparation thereof
EP1156812A4 (de) * 1999-02-23 2004-09-29 Isis Pharmaceuticals Inc Multipartikuläre formulierung
CZ20013103A3 (cs) * 1999-03-02 2002-01-16 The Liposome Company, Inc. Způsob zapouzdřování bioaktivních komplexů do liposomů
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CN1433478A (zh) * 1999-12-30 2003-07-30 诺瓦提斯公司 用于基因治疗的新的胶体合成载体
US6514523B1 (en) 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
JP2004512010A (ja) 2000-03-29 2004-04-22 ディージーアイ・バイオテクノロジーズ・エル・エル・シー インスリン及びｉｇｆ−１受容体のアゴニスト及びアンタゴニスト
ATE442866T1 (de) * 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
JP2004513615A (ja) 2000-06-28 2004-05-13 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
DK2364734T3 (en) * 2000-07-21 2017-10-30 Revance Therapeutics Inc Biological multicomponent transport systems
DE10049010A1 (de) * 2000-10-04 2002-04-18 Boehringer Ingelheim Int Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
AU9418501A (en) * 2000-10-04 2002-04-15 Kyowa Hakko Kogyo Kk Method of coating fine particle with lipid film
EP1355628A2 (de) * 2001-02-01 2003-10-29 Board of Regents, The University of Texas System Stabilisierte aerosollösungen von polymeren zur verabreichung von genen an die lunge
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US20030203865A1 (en) * 2001-04-30 2003-10-30 Pierrot Harvie Lipid-comprising drug delivery complexes and methods for their production
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002309567A1 (en) * 2001-05-16 2002-12-03 The Children's Hospital Of Philadelphia Dna-antibody complexes to enhance gene transfer
AU2002348163A1 (en) * 2001-11-02 2003-05-19 Intradigm Corporation Therapeutic methods for nucleic acid delivery vehicles
CA2476755C (en) 2001-12-17 2014-08-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
AU2003205380A1 (en) * 2002-02-01 2003-09-02 Intradigm Corporation Cationic polymers for use in therapeutic agent delivery
US20060014695A1 (en) * 2002-02-01 2006-01-19 Hamidreza Ghandehari Hpma-polyamine conjugates and uses therefore
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US20060193905A1 (en) * 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
RU2389732C2 (ru) 2003-01-06 2010-05-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
DE10322123A1 (de) * 2003-05-12 2004-12-16 Novosom Ag Injizierbare Depots aus Liposomen und Polymeren zum Peptid- & Proteindelivery
HUE024996T2 (en) 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
PT2656859E (pt) * 2004-03-03 2016-02-24 Revance Therapeutics Inc Aplicação tópica e administração transdérmica de toxinas botulínicas
AU2005251676B2 (en) 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
EP2497831B1 (de) 2004-05-25 2014-07-16 Oregon Health and Science University TB-Impfung unter Verwendung von Impfvektoren auf HCMV-Basis
PL1753456T3 (pl) 2004-06-10 2017-01-31 Omeros Corporation Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
JP2008502622A (ja) 2004-06-14 2008-01-31 サラマ，ゾーセル，ベー． プロリンまたはその誘導体および抗腫瘍抗体からなる抗癌組成物
EP1885746B1 (de) 2005-02-08 2012-01-11 Research Development Foundation Zusammensetzungen in zusammenhang mit löslichen, g-proteingekoppelten rezeptoren (sgpcrs)
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
ATE507236T1 (de) 2005-03-03 2011-05-15 Revance Therapeutics Inc Zusammensetzungen und methoden zur topischen anwendung und zur transdermalen verabreichung eines oligopeptids
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
JP5164830B2 (ja) 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
GB2430881B (en) * 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
US8568740B2 (en) * 2005-11-17 2013-10-29 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
AU2006318212C1 (en) 2005-11-23 2012-08-30 The Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
US20090081157A1 (en) 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
EP2097450A2 (de) * 2006-11-10 2009-09-09 Amgen Inc. Diagnostika und therapeutika auf antikörperbasis
US20100093639A1 (en) * 2006-12-29 2010-04-15 Revance Therapeutics, Inc. Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides
EP3492596A1 (de) 2007-04-09 2019-06-05 University of Florida Research Foundation, Inc. Raav-vektorzusammensetzungen mit tyrosinmodifizierten kapsidproteinen und verfahren zu deren verwendung
GB0707096D0 (en) * 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
EP2772267B1 (de) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogene Zusammensetzungen und Verfahren
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
CA2861667C (en) 2007-10-01 2017-06-13 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system and methods of use
UA97559C2 (uk) * 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти
AU2008338464A1 (en) * 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
AU2009249403A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
GB0904942D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
GB0904941D0 (en) * 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
US8753639B2 (en) 2009-03-31 2014-06-17 University Of Washington Through Its Center For Commercialization Compositions and methods for modulating the activity of complement regulatory proteins on target cells
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
ES2545794T3 (es) 2009-08-28 2015-09-15 Research Development Foundation Análogos de urocortina 2 y usos de los mismos
BR112012008970A2 (pt) 2009-10-16 2019-12-10 Omeros Corp uso de uma composição, e, composição
TW201132353A (en) 2009-12-18 2011-10-01 Amgen Inc WISE binding agents and epitopes
HUE031184T2 (en) 2010-01-27 2017-06-28 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens
ES2711256T3 (es) 2010-04-23 2019-04-30 Univ Florida Composiciones de rAAV-guanilato ciclasa y métodos para tratar la amaurosis congénita de Leber 1 (LCA1)
JP2013533847A (ja) 2010-04-23 2013-08-29 ユニバーシティ オブ マサチューセッツ コレステロール関連障害のａａｖベースの治療
WO2011133890A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
EP2386647A1 (de) * 2010-05-10 2011-11-16 Qiagen GmbH Verfahren zur Transfektion einer eurkaryotischen Zelle
EA027039B1 (ru) 2010-05-14 2017-06-30 Эмджен Инк. Композиции с высокой концентрацией антител
HUE037227T2 (hu) 2010-05-14 2018-08-28 Univ Oregon Health & Science Rekombináns HCMV és RHCMV vektorok és alkalmazásuk
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
EP3578205A1 (de) 2010-08-06 2019-12-11 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012118903A2 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
CN103517920B (zh) 2011-03-25 2018-04-17 安进公司 抗硬化蛋白(sclerostin)抗体晶体及其制剂
EP2691101A2 (de) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
MX355648B (es) 2011-04-08 2018-04-26 Univ Leicester El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
WO2012145624A2 (en) 2011-04-21 2012-10-26 University Of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
WO2012177595A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
MX350198B (es) 2011-07-06 2017-08-30 Novartis Ag Emulsiones aceite en agua que contienen acidos nucleicos.
EP3613852A3 (de) 2011-07-22 2020-04-22 President and Fellows of Harvard College Beurteilung und verbesserung einer nukleasespaltungsspezifität
PT2739311T (pt) 2011-08-04 2018-03-26 Amgen Inc Método para tratamento de defeitos de lacunas ósseas
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9849087B2 (en) 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
EP2797953B1 (de) 2011-12-28 2020-06-03 Amgen Inc. Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern
CA2863083C (en) 2012-01-26 2023-09-19 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US20130273053A1 (en) 2012-04-06 2013-10-17 University Of Leicester Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
RU2709351C2 (ru) 2012-06-18 2019-12-17 Омерос Корпорейшн Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
CA2897941A1 (en) 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
MX2015009901A (es) 2013-02-01 2016-04-06 Santa Maria Biotherapeutics Inc Administración de un compuesto de antiactivina a a un sujeto.
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
BR112015023502A2 (pt) 2013-03-15 2017-07-18 Glaxosmithkline Biologicals Sa composição, e, métodos para intensificar uma resposta imune e melhorar ou prevenir substancialmente uma doença infecciosa, uma doença autoimune, ou uma condição alérgica em um indivíduo
JP6549554B2 (ja) 2013-03-15 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コレステロール流出を刺激する、減少した毒性を有するペプチド
PL2970389T3 (pl) * 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
DK3019619T3 (da) 2013-07-11 2021-10-11 Modernatx Inc Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
JP6896421B2 (ja) 2013-08-21 2021-06-30 キュアバック アーゲー 呼吸器合胞体ウイルス（ｒｓｖ）ワクチン
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
EP3052106A4 (de) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynukleotide zur codierung immunmodulierender polypeptide
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
DK3057993T3 (en) 2013-10-17 2020-11-16 Omeros Corp Method for Treating Conditions Associated with MASP-2 Dependent Complement
DK3066201T3 (en) 2013-11-07 2018-06-06 Editas Medicine Inc CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
CA2930973A1 (en) 2013-11-22 2015-05-28 Pal SAERTROM C/ebp alpha short activating rna compositions and methods of use
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
AU2015231294B2 (en) 2014-03-18 2020-10-29 University Of Massachusetts rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
CA2946751A1 (en) 2014-04-23 2015-10-29 Modernatx, Inc. Nucleic acid vaccines
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
SI3766916T1 (sl) 2014-06-25 2023-01-31 Acuitas Therapeutics Inc. Formulacije novih lipidov in lipidnih nanodelcev za dostavo nukleinskih kislin
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
EP3169693B1 (de) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimäre polynukleotide
EP3171895A1 (de) 2014-07-23 2017-05-31 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von intrabodys
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10029012B2 (en) * 2014-09-05 2018-07-24 University Of Pittsuburgh—Of The Commonwealth System Of Higher Education Peptide-mediated intravesical delivery of therapeutic and diagnostic agents
US10711270B2 (en) 2014-10-03 2020-07-14 University Of Massachusetts High efficiency library-identified AAV vectors
EP3207150B1 (de) 2014-10-14 2021-04-28 Research Development Foundation Verfahren zur erzeugung von manipulierten enzymen
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
US10889812B2 (en) 2014-10-24 2021-01-12 University Of Maryland, Baltimore Short non-coding protein regulatory RNAs (sprRNAs) and methods of use
EP3212165B1 (de) 2014-10-30 2024-02-28 President and Fellows of Harvard College Freisetzung von negativ geladenen proteinen unter verwendung von kationischen lipiden
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
WO2016100575A1 (en) 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease
US20170369872A1 (en) 2014-12-18 2017-12-28 Alnylam Pharmaceuticals, Inc. Reversir tm compounds
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
CA3019315A1 (en) 2015-04-23 2016-10-27 University Of Massachusetts Modulation of aav vector transgene expression
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
WO2017004143A1 (en) 2015-06-29 2017-01-05 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
ES2937963T3 (es) 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3362102A1 (de) 2015-10-14 2018-08-22 Life Technologies Corporation Ribonukleoprotein-transfektionsmittel
MA46024A (fr) 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de l'herpès simplex
CN108472354A (zh) 2015-10-22 2018-08-31 摩登纳特斯有限公司 呼吸道合胞病毒疫苗
EP3364981A4 (de) 2015-10-22 2019-08-07 ModernaTX, Inc. Impfstoff gegen das humane cytomegalovirus
PL3718565T3 (pl) 2015-10-22 2022-09-19 Modernatx, Inc. Szczepionki przeciwko wirusom układu oddechowego
EA201891001A1 (ru) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したＣａｓ９蛋白質
WO2017083371A1 (en) 2015-11-09 2017-05-18 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
EP3383418B1 (de) 2015-12-04 2021-10-20 Board of Regents, The University of Texas System Slc45a2-peptide für immuntherapie
CA3007955A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Lipid nanoparticles for delivery of therapeutic agents
PL3394030T3 (pl) 2015-12-22 2022-04-11 Modernatx, Inc. Związki i kompozycje do wewnątrzkomórkowego dostarczania środków
DK3394093T3 (da) 2015-12-23 2022-04-19 Modernatx Inc Fremgangsmåder til anvendelse af ox40-ligand-kodende polynukleotider
SG11201805695SA (en) 2016-01-05 2018-07-30 Univ Leicester Methods for inhibiting fibrosis in a subject in need thereof
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
EP4094780A3 (de) 2016-02-12 2023-02-08 University of Massachusetts Anti-angiogene mirna-therapeutika zur hemmung der neovaskularisation der hornhaut
ES2923877T3 (es) 2016-03-01 2022-10-03 Univ Florida Vectores VAA para el tratamiento de la retinitis pigmentosa dominante
KR102336362B1 (ko) 2016-03-03 2021-12-08 보이저 테라퓨틱스, 인크. 비-바이러스 유전자 전달을 위한 폐쇄형-말단 선형 듀플렉스 dna
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN115137816A (zh) 2016-03-31 2022-10-04 奥默罗斯公司 抑制有需要的受试者的血管发生的方法
JP7262100B2 (ja) 2016-04-29 2023-04-21 アイカーン スクール オブ メディスン アット マウント サイナイ 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化
EP3468609A1 (de) * 2016-06-09 2019-04-17 CureVac AG Kationische träger zur nukleinsäurefreisetzung
WO2017212009A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US20190185864A1 (en) 2016-08-23 2019-06-20 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
AU2017341849B2 (en) 2016-10-13 2024-03-21 University Of Massachusetts AAV capsid designs
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CA3043033A1 (en) * 2016-11-10 2018-05-17 Translate Bio, Inc. Improved ice-based lipid nanoparticle formulation for delivery of mrna
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
HUE060693T2 (hu) 2017-03-15 2023-04-28 Modernatx Inc Vegyület és készítmények terápiás szerek intracelluláris bejuttatására
EP3596042B1 (de) 2017-03-15 2022-01-12 Modernatx, Inc. Kristallformen von aminolipiden
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
CA3059112A1 (en) 2017-04-05 2018-10-11 University Of Massachusetts Cep290 minigene therapy
CN110799492B (zh) 2017-04-28 2023-06-27 爱康泰生治疗公司 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
EP3625345B1 (de) 2017-05-18 2023-05-24 ModernaTX, Inc. Modifizierte messenger-rna mit funktionellen rna-elementen
MA49395A (fr) 2017-06-14 2020-04-22 Modernatx Inc Polynucléotides codant pour le facteur viii de coagulation
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
US20200138921A1 (en) 2017-06-23 2020-05-07 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating diseases characterized by synaptic dysfunction and neurodegeneration including alzheimer's disease
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
TW202402809A (zh) 2017-08-15 2024-01-16 美商歐米諾斯公司 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
JP7275111B2 (ja) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の生成方法
EP4219715A3 (de) 2017-09-08 2023-09-06 MiNA Therapeutics Limited Stabilisierte cebpa-sarna-zusammensetzungen und verfahren zur verwendung
WO2019048631A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited SMALL HNF4A ACTIVATOR RNA COMPOSITIONS AND METHODS OF USE
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US20210236644A1 (en) 2017-11-10 2021-08-05 Cocoon Biotech Inc. Ocular applications of silk-based products
WO2019104160A2 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
JP7423522B2 (ja) 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド
MA50802A (fr) 2017-11-22 2020-09-30 Modernatx Inc Polynucléotides codant pour des sous-unités alpha et bêta de propionyl-coa carboxylase pour le traitement de l'acidémie propionique
EP3735270A1 (de) 2018-01-05 2020-11-11 Modernatx, Inc. Für anti-chikungunya-virus-antikörper codierende polynukleotide
KR20200135433A (ko) 2018-03-23 2020-12-02 유니버시티 오브 매사추세츠 골 장애 치료를 위한 유전자 치료제
KR20200138254A (ko) 2018-03-30 2020-12-09 암젠 인크 C-말단 항체 변이체
EP3773745A1 (de) 2018-04-11 2021-02-17 ModernaTX, Inc. Messenger-rna mit funktionalen rna-elementen
WO2019197845A1 (en) 2018-04-12 2019-10-17 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
US11904081B2 (en) 2018-05-11 2024-02-20 Lupagen, Inc. Systems and methods for closed loop, real-time modifications of patient cells
EP3794130A4 (de) 2018-05-16 2022-07-27 Synthego Corporation Verfahren und systeme für design und verwendung von guide-rna
MA52709A (fr) 2018-05-23 2021-03-31 Modernatx Inc Administration d'adn
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
US20210170005A1 (en) 2018-08-15 2021-06-10 University Of Florida Research Foundation, Inc. Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
WO2020047201A1 (en) 2018-09-02 2020-03-05 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
WO2020056161A1 (en) 2018-09-12 2020-03-19 University Of Florida Research Foundation, Inc. Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
EP3849594A2 (de) 2018-09-13 2021-07-21 Modernatx, Inc. Für verzweigtkettige alpha-ketosäuredehydrogenasekomplexe e1-alpha, e1-beta und e2 untereinheiten codierende polynukleotide zur behandlung von ahornsirupkrankheit
MA53609A (fr) 2018-09-13 2021-07-21 Modernatx Inc Polynucléotides codant la glucose-6-phosphatase pour le traitement de la glycogénose
AU2019339430A1 (en) 2018-09-14 2021-04-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1 for the treatment of Crigler-Najjar Syndrome
JP2022500543A (ja) 2018-09-19 2022-01-04 モデルナティーエックス， インコーポレイテッド 高純度ｐｅｇ脂質及びそれらの使用
EP3852732A1 (de) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg-lipide und deren verwendung
WO2020069169A1 (en) 2018-09-27 2020-04-02 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
CN113164625A (zh) 2018-09-28 2021-07-23 哈佛大学的校长及成员们 用于基因表达的突变体反向四环素反式激活因子
MX2021003663A (es) 2018-09-28 2021-05-28 Harvard College Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos.
US20220001026A1 (en) 2018-11-08 2022-01-06 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
US20220033824A1 (en) 2018-11-29 2022-02-03 University Of Massachusetts Modulation of sptlc1 via recombinant adeno-associated vectors
EP3908568A1 (de) 2019-01-11 2021-11-17 Acuitas Therapeutics, Inc. Lipide zur lipidnanopartikelfreisetzung von wirkstoffen
JP2022523055A (ja) 2019-01-25 2022-04-21 シンテゴ コーポレイション Ｃｒｉｓｐｒ活性をモジュレートするための系および方法
EP3927380A1 (de) 2019-02-22 2021-12-29 University of Massachusetts Oxr1-gentherapie
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
EP3953473A1 (de) 2019-04-12 2022-02-16 MiNA Therapeutics Limited Sirt1-sarna-zusammensetzungen und verfahren zur verwendung
EP3959232A4 (de) 2019-04-24 2023-01-18 University of Massachusetts Aav-capsid-chimäre antigenrezeptoren und verwendungen davon
EP3962521A1 (de) 2019-05-02 2022-03-09 University of Florida Research Foundation, Inc. Zusammensetzungen zur behandlung von diffusem intrinsischem ponsgliom
JP2022532078A (ja) 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ 皮膚及び創傷のための組成物並びにその使用の方法
EP3987027A1 (de) 2019-06-24 2022-04-27 ModernaTX, Inc. Endonukleaseresistente messenger-rna und verwendungen davon
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
US20230000997A1 (en) 2019-08-06 2023-01-05 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
US20230097090A1 (en) 2019-08-14 2023-03-30 Acuitas Therapeutics, Inc. Improved lipid nanoparticles for delivery of nucleic acids
KR20220079857A (ko) 2019-09-13 2022-06-14 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 Aav-상용성 라미닌-링커 중합 단백질
JP2022548304A (ja) 2019-09-19 2022-11-17 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための分岐状尾部脂質化合物及び組成物
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
CA3168055A1 (en) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
EP4127186A1 (de) 2020-03-24 2023-02-08 Generation Bio Co. Nichtvirale dna-vektoren und verwendungen davon zur expression von gaucher-therapeutika
US20230138409A1 (en) 2020-03-24 2023-05-04 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
MX2022012279A (es) 2020-03-31 2023-02-23 Univ Massachusetts Variantes de capsides de aav y usos de los mismos.
US20230226169A1 (en) 2020-04-01 2023-07-20 University Of Florida Research Foundation Incorporated Multilamellar rna nanoparticle vaccine against sars-cov-2
EP4150626A1 (de) 2020-04-29 2023-03-22 The Broad Institute Inc. Durch maschinelles lernen beschleunigte proteinzüchtung durch fitnessvorhersage
US20210346416A1 (en) * 2020-05-05 2021-11-11 Ralph Lipp Pharmaceutical Compositions and Methods for their Use in Antiviral Therapy
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
AU2021275239A1 (en) 2020-05-21 2022-12-15 Board Of Regents, The University Of Texas System T cell receptors with VGLL1 specificity and uses thereof
JP2023527875A (ja) 2020-06-01 2023-06-30 モダーナティエックス・インコーポレイテッド フェニルアラニンヒドロキシラーゼバリアント及びその使用
IL300526A (en) 2020-08-17 2023-04-01 Massachusetts Inst Technology Approaches to SHANK3 gene therapy
US20230406895A1 (en) 2020-11-13 2023-12-21 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
EP4255457A1 (de) 2020-12-03 2023-10-11 University of Massachusetts Entwicklung von neuen gentherapeutika für fibrodysplasia ossificans progressiva
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2022198101A1 (en) 2021-03-19 2022-09-22 Trained Therapeutix Discovery, Inc. Compounds for regulating trained immunity, and their methods of use
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
JP2024512026A (ja) 2021-03-24 2024-03-18 モデルナティエックス インコーポレイテッド オルニチントランスカルバミラーゼ欠損症の治療を目的とした脂質ナノ粒子及びオルニチントランスカルバミラーゼをコードするポリヌクレオチド
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
EP4314292A1 (de) 2021-03-26 2024-02-07 MiNA Therapeutics Limited Tmem173-sarna-zusammensetzungen und verfahren zur verwendung
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
WO2022232286A1 (en) 2021-04-27 2022-11-03 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
IL308404A (en) 2021-04-27 2024-01-01 Generation Bio Co Non-viral DNA vectors expressing therapeutic antibodies and uses thereof
KR20240017813A (ko) 2021-05-10 2024-02-08 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 신경질환 치료용 약학적 조성물
EP4355882A2 (de) 2021-06-15 2024-04-24 Modernatx, Inc. Manipulierte polynukleotide zur zelltyp- oder mikroumgebungsspezifischen expression
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
CA3233097A1 (en) 2021-09-30 2023-04-06 Katherine Diane GRIBBLE Compositions and methods for treating kcnq4-associated hearing loss
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
TW202334080A (zh) 2021-11-08 2023-09-01 美商歐納醫療公司 用於遞送環狀聚核苷酸之脂質奈米粒子組合物
WO2023095874A1 (ja) * 2021-11-25 2023-06-01 国立大学法人長崎大学 脂質性化合物、リポソーム、エクソソーム、脂質ナノ粒子及びドラッグデリバリーシステム
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
CN114306641A (zh) * 2022-02-17 2022-04-12 大连民族大学 一种胆固醇氨基衍生物-蔗糖酯型阳离子脂质体/基因复合物及其制备方法
WO2023164545A1 (en) 2022-02-23 2023-08-31 Massachusetts Institute Of Technology Methods for upregulating shank3 expression
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023196851A1 (en) 2022-04-06 2023-10-12 President And Fellows Of Harvard College Reversing aging of the central nervous system
WO2024026254A1 (en) 2022-07-26 2024-02-01 Modernatx, Inc. Engineered polynucleotides for temporal control of expression
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5545412A (en) 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5342921A (en) 1985-03-28 1994-08-30 Chiron Corporation Superoxide dismutase fusion polypeptides for expression of mammalian proteins
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US5540933A (en) * 1985-05-31 1996-07-30 La Jolla Cancer Research Foundation Isolation and use of fibronectin receptor
EP0238645A1 (de) 1985-10-03 1987-09-30 Biotechnology Research Partners, Ltd. Neue arzneimittel verabreichende systeme auf der basis von lipoproteinen
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5560929A (en) 1986-08-18 1996-10-01 The Dow Chemical Company Structured copolymers and their use as absorbents, gels and carriers of metal ions
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5283634A (en) * 1987-06-18 1994-02-01 Canon Kabushiki Kaisha Luminance signal correcting method
US5008202A (en) * 1988-11-29 1991-04-16 Sequoia Turner Corporation Blood diluent for red blood cell analysis
US5196510A (en) 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
DE3908047A1 (de) 1989-03-13 1990-09-20 Desitin Arzneimittel Gmbh Hochdisperse pharmazeutische zusammensetzung
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5165925A (en) 1989-05-02 1992-11-24 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Vaccine for immunizing fish against infectious pancreatic necrosis virus
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
ES2091916T3 (es) 1989-12-21 1996-11-16 Whitehead Biomedical Inst Metodo para suministrar moleculas en el interior de celulas eucarioticas.
US5583198A (en) 1989-12-22 1996-12-10 Commonwealth Scientific And Industrial Research Organization Amino acids, peptides or derivatives thereof coupled to fats
US5705187A (en) 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6147204A (en) 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
NZ239893A (en) 1990-09-25 1993-11-25 Hoechst Japan A method for introducing a foreign dna into a cell
DK0560932T3 (de) 1990-12-04 1997-02-17 Univ Texas
US5589392A (en) 1991-01-14 1996-12-31 Stratagene Nucleic acid construct encoding a nuclear transport peptide operatively linked to an inducible promoter
US5328984A (en) 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
AU667680B2 (en) * 1991-08-07 1996-04-04 Albert Einstein College Of Medicine Of Yeshiva University Proliferation of hepatocyte precursors
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
DE4139001A1 (de) 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur einschleusung von nukleinsaeuren in zellen
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
EP0643835B1 (de) 1992-02-24 2001-04-18 Genelabs Technologies, Inc. Htlv-i/htlv-ii assay und verfahren
IL101241A (en) 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
JPH07505283A (ja) 1992-03-20 1995-06-15 ベイラー・カレッジ・オブ・メディシン Ｄｎａトランスポーター系および使用方法
US6033884A (en) * 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
EP1236473A3 (de) 1992-04-03 2003-01-15 The Regents Of The University Of California Selbst zusammenbaubares system zur verabreichung von polynukleotiden
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5266106A (en) 1992-10-22 1993-11-30 Xerox Corporation Ink compositions with dendrimer grafts
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
AU6133394A (en) 1993-02-09 1994-08-29 Scripps Research Institute, The Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
US5532142A (en) 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
WO1994018834A1 (en) 1993-02-16 1994-09-01 Virginia Tech Intellectual Properties, Inc. Polyelectrolyte dna conjugation and genetic transformation of an animal
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
WO1994023751A1 (de) 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
US5554382A (en) 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
US5776486A (en) 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
WO1994027435A1 (en) 1993-06-01 1994-12-08 Life Technologies, Inc. Genetic immunization with cationic lipids
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
EP0708637B1 (de) 1993-07-14 2004-01-28 The Regents of the University of California Sich selbst zusammensetzendes polynukleotid-abgabesystem, das dendrimer-polykationen enthält
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AU688428B2 (en) 1993-11-09 1998-03-12 Johns Hopkins University, The Generation of high titers of recombinant AAV vectors
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
ATE190663T1 (de) 1994-01-28 2000-04-15 Targeted Genetics Corp Cd69 - transkriptionsregulierende elemente
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6075012A (en) 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
ES2316148T3 (es) 1994-03-23 2009-04-01 Ohio University Acidos nucleicos compactados y su suministro a celulas.
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
FR2719316B1 (fr) * 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
AUPM747694A0 (en) 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5744355A (en) * 1994-10-18 1998-04-28 Mayo Foundation For Medical Education And Research cDNA cloning and expression of human liver estrogen sulfotransferase
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US5587441A (en) 1994-11-08 1996-12-24 Cornell Research Foundation, Inc. Hyperbranched polymers from AB monomers
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5939401A (en) 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5635487A (en) 1994-12-29 1997-06-03 Wolff; Jon A. Amphipathic, micellar delivery systems for biologically active polyions
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
JP4335310B2 (ja) 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
EP0874910A4 (de) 1995-06-07 1999-04-21 Life Technologies Inc Durch peptide erhöhte kationische lipid transfektionen
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US20030069173A1 (en) 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US5753262A (en) 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5908777A (en) 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6033848A (en) 1995-08-01 2000-03-07 Incyte Pharmaceuticals, Inc. Human ice homolog
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US6086913A (en) 1995-11-01 2000-07-11 University Of British Columbia Liposomal delivery of AAV vectors
US6126964A (en) 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
AUPN741696A0 (en) 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US5811297A (en) 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
JPH09268195A (ja) * 1996-04-02 1997-10-14 Mitsubishi Chem Corp 蔗糖脂肪酸エステルの製造方法
CA2264140A1 (en) 1996-08-26 1998-03-05 Transgene S.A. Cationic lipid-nucleic acid complexes
US5905777A (en) * 1996-09-27 1999-05-18 At&T Corp. E-mail paging system
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6224903B1 (en) 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
JP2001510457A (ja) 1996-11-12 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ送達に有効な、脂質―核酸複合体の安定な製剤の調製
US6017735A (en) 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US5948925A (en) 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
EP2138191A1 (de) 1998-01-05 2009-12-30 University Of Washington Erhöhter Transport unter Benutzung membranzerstörender Stoffe
US6271209B1 (en) 1998-04-03 2001-08-07 Valentis, Inc. Cationic lipid formulation delivering nucleic acid to peritoneal tumors
US6043390A (en) 1998-04-03 2000-03-28 The Regents Of The University Of California Pentaerythritol lipid derivatives and nucleic-acid complexes
US6011202A (en) * 1998-07-28 2000-01-04 Delta And Pine Land Company Soybean cultivar 95-00981
JP4854853B2 (ja) 1998-11-12 2012-01-18 ライフ テクノロジーズ コーポレーション トランスフェクション薬剤
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6037176A (en) 1999-06-25 2000-03-14 Isis Pharmaceuticals Inc. Antisense inhibition of integrin beta 3 expression
AU2002232387A1 (en) 2000-10-27 2002-05-06 Invitrogen Corporation Method for introducing antisense oligonucleotides into eucaryotic cells
US20040102606A1 (en) 2001-04-24 2004-05-27 Danuta Balicki Histone H2A -derived peptides useful in gene delivery
US20030203865A1 (en) 2001-04-30 2003-10-30 Pierrot Harvie Lipid-comprising drug delivery complexes and methods for their production
EP1587908A4 (de) 2003-01-09 2008-02-20 Invitrogen Corp Zelluläre zuführung und aktivierung von polypeptid-nukleinsäurekomplexen

Also Published As

Publication number Publication date
US5795587A (en) 1998-08-18
US20130281382A1 (en) 2013-10-24
CA2211118C (en) 2009-06-30
CN1177291A (zh) 1998-03-25
JP4074338B2 (ja) 2008-04-09
US20120178702A1 (en) 2012-07-12
US20100184953A1 (en) 2010-07-22
MX9705572A (es) 1998-06-28
US7655468B2 (en) 2010-02-02
AU709773B2 (en) 1999-09-09
US8771728B2 (en) 2014-07-08
US7993672B2 (en) 2011-08-09
CA2211118A1 (en) 1996-08-01
DK0814777T3 (da) 2003-03-03
EP0814777A1 (de) 1998-01-07
JPH10512882A (ja) 1998-12-08
IL116856A0 (en) 1996-07-23
ES2186769T3 (es) 2003-05-16
WO1996022765A1 (en) 1996-08-01
EP0814777B1 (de) 2002-11-13
ZA96503B (en) 1996-08-07
DE69624801T2 (de) 2003-04-10
ATE227563T1 (de) 2002-11-15
AU4703796A (en) 1996-08-14
PT814777E (pt) 2003-03-31
US20080153166A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
ATE227563T1 (de) Stabile arzneistoffabgabekomplexe mit lipiden und verfahren zu deren herstellung
AU7576896A (en) Lipopolyamines as transfection agents and their pharmaceutical applications
ATE264671T1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
ATE41307T1 (de) Waessrige, eine fettloesliche wirksubstanz enthaltende loesung sowie verfahren zu deren herstellung.
FI103278B1 (fi) Menetelmä biologisesti aktiivisen TGF- :n kaltaisen proteiinin tuottamiseksi
NO20002788D0 (no) Nye forbindelser
HUP0004423A2 (hu) Acil-szulfamoil-benzoesav-amidok, az ezeket tartalmazó haszonnövényvédő készítmények és eljárás az előállításukra
DE59303365D1 (de) Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
MEP10408A (en) Platinum derivative pharmaceutical formulations
DE3854950D1 (de) Vascular-antikoagulierende Proteine, DNA die diese kodieren, Verfahren zu deren Herstellung sowie deren Verwendung
ES2195040T3 (es) Conjugado que incluye un principio activo, un polipeptido y varios polieteres y su uso como medicamento.
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
ATE226065T1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
DE68906572T2 (de) Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
FR2725718B1 (fr) Bis-2-aminopyridines, leur procede de preparation et leurs applications
DE3576155D1 (de) Diazohydroxypyrazinverbindungen, verfahren zu deren herstellung und verwendung.
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
DE59004814D1 (de) t-PA-Solubilisierung.
DE68909451D1 (de) Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
AR003920A1 (es) Metodo para producir complejos droga/lipidos que tienen cargas positivas en exceso con respecto a la droga y los complejos droga/lipidos obtenidos condicho metodo y metodo para dispensar una droga a una persona.
IT1263913B (it) Composti terapeuticamente attivi, utili per il trattamento di malattieconnesse con alterata funzionalita' del sistema immunitario, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
DE59105961D1 (de) 2,13-disubstituierte ergoline, deren herstellung und verwendung in arzneimitteln.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition